Stenting (Pre-Clinical)

  1. Yazdani SK, Sheehy A, Nakano M, Nakazawa G, Vorpahl M, Otsuka F, Donn RS, Perkins LE, Simonton CA, Kolodgie FD, Virmani R. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. J Invasive Cardiol.  2013 PubMed PMID:23913602
  2. Lane JP, Perkins LE, Sheehy AJ, Pacheco EJ, Frie MP, Lambert BJ, Rapoza RJ, Virmani R. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv.  2014 PubMed PMID:24835327
  3. Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv.  2014 PubMed PMID 24895447
  4. Habib A, Karmali V, John MC, Polavarapu R, Nakazawa G, Pachura K, Davis T, Kolodgie FD, Virmani R, Finn AV. Everolimus-eluting stents improve vascular response in a diabetic animal model. Circ Cardiovasc Interv.  2014. PubMed PMID:24915972
  5. Sheehy A, Hsu S, Sinn I, Tai J, Kolodgie FD, Nakazawa G, Yazdani SK, Quee SC, Virmani R, Polyakov I. Vascular response to coronary artery stenting in mature and juvenile swine. Cardiovasc Revasc Med. Jul 7 2011.
  6. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. Feb 1 2011;4(1):38-46.
  7. Kappert U, Ouda A, Virmani R, Mettler D, Matschke K, Demertzis S. The C-Port xV(R) vascular anastomosis system: results from an animal trial. Thorac Cardiovasc Surg. Jun 2011;59(4):222-226.
  8. Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY, Parker S, Rowland SM, Kolodgie FD, Leon MB, Virmani R. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv. Jan 2010;3(1):68-75.
  9. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv. Jun 1 2010;3(3):257-266.
  10. Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, Tai JT, Abraham GM, Pacetti SD, Chan YF, Nakazawa G, Kolodgie FD, Virmani R, Ding NN, Coleman LA. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials. Feb 2010;31(4):648-657.
  11. Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent expansion and neointimal proliferation of oversized Nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. Jul 2009;32(4):720-726.
  12. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. Jul 14 2009;120(2):141-149, 141-142.
  13. Finn AV, John M, Nakazawa G, Polavarapu R, Karmali V, Xu X, Cheng Q, Davis T, Raghunathan C, Acampado E, Ezell T, Lajoie S, Eppihimer M, Kolodgie FD, Virmani R, Gold HK. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. Circ Res. Nov 6 2009;105(10):1003-1012.
  14. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. Jul 29 2008;52(5):333-342.
  15. Joner M, Morimoto K, Kasukawa H, Steigerwald K, Merl S, Nakazawa G, John MC, Finn AV, Acampado E, Kolodgie FD, Gold HK, Virmani R. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol. Nov 2008;28(11):1960-1966.
  16. John MC, Wessely R, Kastrati A, Schomig A, Joner M, Uchihashi M, Crimins J, Lajoie S, Kolodgie FD, Gold HK, Virmani R, Finn AV. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC Cardiovasc Interv. Oct 2008;1(5):535-544.
  17. Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, Acampado E, Kolodgie FD, Vassanelli C, Virmani R. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol. Jul 10 2007;50(2):176-185.
  18. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK, Virmani R. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol. Jan 2007;27(1):182-189.
  19. Pakala R, Dilcher C, Baffour R, Hellinga D, Seabron R, Joner M, Kolodgie F, Virmani R, Waksman R. Peroxisome proliferator-activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. J Cardiovasc Pharmacol. Dec 2006;48(6):299-305.
  20. Cheema AN, Hong T, Nili N, Segev A, Moffat JG, Lipson KE, Howlett AR, Holdsworth DW, Cole MJ, Qiang B, Kolodgie F, Virmani R, Stewart DJ, Strauss BH. Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor. J Am Coll Cardiol. Mar 7 2006;47(5):1067-1075.
  21. Strauss BH, Segev A, Wright GA, Qiang B, Munce N, Anderson KJ, Leung G, Dick AJ, Virmani R, Butany J. Microvessels in chronic total occlusions: pathways for successful guidewire crossing? J Interv Cardiol. Dec 2005;18(6):425-436.
  22. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. Jul 12 2005;112(2):270-278.
  23. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. Oct 6 2004;44(7):1373-1385.
  24. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart. Feb 2003;89(2):133-138.
  25. Virmani R, Farb A, Kolodgie FD. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz. Feb 2002;27(1):1-6.
  26. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. Oct 1 2002;106(14):1867-1873.
  27. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N, Soon-Shiong P, Virmani R. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation. Sep 3 2002;106(10):1195-1198.
  28. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation. Oct 29 2002;106(18):2379-2384.
  29. Shroff S, Farb A, John M, Virmani R. Neointima formation inhibited, but healing incomplete 12 months after deployment of high-dose 32P beta-emitting stents. Cardiovasc Radiat Med. Jan 1 2001;2(1):56.
  30. Farb A, Shroff S, John M, Sweet W, Virmani R. Late arterial responses (6 and 12 months) after (32)P beta-emitting stent placement: sustained intimal suppression with incomplete healing. Circulation. Apr 10 2001;103(14):1912-1919.
  31. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. Jul 24 2001;104(4):473-479.
  32. Kim WH, Hong MK, Virmani R, Kornowski R, Jones R, Leon MB. Histopathologic analysis of in-stent neointimal regression in a porcine coronary model. Coron Artery Dis. May 2000;11(3):273-277.
  33. Farb A, Tang AL, Shroff S, Sweet W, Virmani R. Neointimal responses 3 months after (32)P beta-emitting stent placement. Int J Radiat Oncol Biol Phys. Oct 1 2000;48(3):889-898.